Literature DB >> 19023521

The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in women below 50 of the Malmö Thrombophilia Study (MATS).

Nazim Isma1, Thomas Breslin, Bengt Lindblad, Peter J Svensson.   

Abstract

The aim of this study was to investigate a relationship between FVL-mutation and levels of haemoglobin (Hb) in patients with venous thromboembolism (VTE). From March 1998 to December 2005, 927 consecutive patients with objectively diagnosed VTE were registered in the Malmö Thrombophilia Study (MATS). Female patients with FVL-mutation below 50 years of age had significantly higher median-Hb (133 vs. 126 g/l; P < 0.001) compared to female patients below the age of 50 years without FVL. No significant difference could be found for men or women above 50 years of age or men below 50 years of age. Female patients below the age of 50 years with FVL-mutation and VTE are associated with higher median Hb, and this finding is in accordance with earlier hypothesis that FVL-mutation may have constituted an evolutionary selection advantage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023521     DOI: 10.1007/s11239-008-0293-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  16 in total

1.  Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden--an evolutionary advantage?

Authors:  P G Lindqvist; B Zöller; B Dahlbäck
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

2.  Venous thrombosis: the role of genes, environment, and behavior.

Authors:  Frits R Rosendaal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

Review 3.  Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.

Authors:  B Dahlbäck
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

4.  Activated protein C resistance (FV:Q506) and pregnancy.

Authors:  P G Lindqvist; P J Svensson; K Marsaál; L Grennert; M Luterkort; B Dahlbäck
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

5.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

6.  Resistance to activated protein C as a basis for venous thrombosis.

Authors:  P J Svensson; B Dahlbäck
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

7.  Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.

Authors:  Bryce A Kerlin; S Betty Yan; Berend H Isermann; John T Brandt; Rashmi Sood; Bruce R Basson; David E Joyce; Hartmut Weiler; Jean-Francois Dhainaut
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

8.  Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies.

Authors:  Hartmut Weiler; Bryce Kerlin; Mary C Lytle
Journal:  Crit Care Med       Date:  2004-05       Impact factor: 7.598

9.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

10.  An attempt to estimate the true rate of maternal mortality, sixteenth to eighteenth centuries.

Authors:  B M Dobbie
Journal:  Med Hist       Date:  1982-01       Impact factor: 1.419

View more
  1 in total

1.  Factor v leiden and inflammation.

Authors:  Silvia Perez-Pujol; Omer Aras; Gines Escolar
Journal:  Thrombosis       Date:  2012-05-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.